MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-Year results, late toxicity, and second tumors

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 529-535

  Gobbi, Paolo G ^a   Broglia, Chiara ^a   Levis, Alessandro ^c   La Sala, Antonio ^d   Valentino, Francesco ^a   Chisesi, Teodoro ^e   Sacchi, Stefano ^f   Corbella, Franco ^b   Cavanna, Luigi ^h   Iannitto, Emilio ^g   Pavone, Vincenzo ⁱ   Molica, Stefano ^j   Corazza, Gino Roberto ^a   Federico, Massimo ^f  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c C Arrigo Children's Hospital   (Italy)

^d Casa Sollievo della Sofferenza   (Italy)

^e Ospedale Civile SS Giovanni e Paolo   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g Cattedra ed UO di Ematologia con trapianto   (Italy)

^h Ospedale Civile   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j PUGLIESE CIACCIO HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RADIATION DOSE; SECOND CANCER; STOMACH HEMORRHAGE; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG TOXICITY; EPIRUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; LOMUSTINE; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PILOT PROJECTS; PREDNISONE; PROCARBAZINE; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE; VINDESINE;

EID: 31544453649     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1707     Document Type: Article

References (35)

1. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
2. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-years results. Ann Intern Med 1986;104:739-46.
3. Longo DL, Duffey PL, De Vita VT, Jr., et al. Treatment of advanced-stage Hodgkin's disease: alternating non-cross-resistant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991;9:1409-20.
4. Jones SE, Haut A, Weick JK, et al. Comparison of Adriamycin-containing chemotherapy (MOP-BAP) with MOPP-bleomycin in the management of advanced Hodgkin's disease. Cancer 1983;51:1339-47.
5. Wagener DJT, Burgers JMV, Dekker AW, et al. Sequential non-cross-resistant chemotherapy regimens (MOPP and CAVmP) in Hodgkin's disease stage IIIB and IV. Cancer 1983;52:1558-62.
6. Gams RA, Omura GA, Velez-Garcia E, Kellermeyer R, Raney M, Bartolucci AA. Alternating sequential combination chemotherapy in the management of advanced Hodgkin's disease. Cancer 1986;58:1963-8.
7. Klimo P, Connors JM. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988;25:34-40.
8. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14:1421-30.
9. Radford JA, Crowther D, Rohatiner AZS, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995;13:2379-85.
10. Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998;9:73-8.
11. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997;8:143-8.
12. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95.
13. Strauss D, Myers J, Lee BJ, et al. Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Am J Med 1984;72:270-8.
14. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977;61:1307-13.
15. Gobbi PG, Pieresca C, Federico M, et al. MOPP/EVB/CAD chemotherapy with or without limited radiotherapy in advanced or unfavorable presenting Hodgkin's disease: a report from Italian Lymphoma Study Group. J Clin Oncol 1993;11:712-9.
16. Gobbi PG, Pieresca C, Ghirardelli ML, et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 1998;91:1-10.
17. Gobbi PG, Broglia C, Bertè R, et al. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease. Haematologica 2000;85:722-8.
18. Chisesi T, Federico M, Levis A, et al. ABVD versus Stanford V versus MEC in unfavorable Hodgkin's lymphoma: results of randomized trial. Ann Oncol 2002;13:102-6.
19. Lister TA, Crowther D, Sutcliffe SB, et al. Report of the committee convened to discuss the evaluation and staging patients with Hodgkin's disease. J Clin Oncol 1989;7:1630-6.
20. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
21. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65-74.
22. DeVita VT, Hubbard SM, Longo DL. The chemotherapy of lymphoma: looking back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1987;47:5810-24.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
24. Dixon DO, McLauhlin P, Hagemaister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987;5:1670-8.
25. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications; 1987. p. 186-209.
26. Radford JA, Rohatiner AZS, Ryder WDJ, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002;20:2988-94.
27. Glick JK, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998;16:19-26.
28. Horning S, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of prospective clinical trial. J Clin Oncol 2002;20:630-7.
29. Sieber M, Tesch H, Fistner B, et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABV and consolidating radiotherapy: final results of the German Hodgkin's lymphoma study group HD6 trial. Ann Oncol 2004;15:276-82.
30. Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's lymphoma study group. J Clin Oncol 2003;21:3440-6.
31. Hasenclever D, Diehl V. A prognostic score to predict tumor control in advanced Hodgkin's disease. International Prognostic Factors on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14.
32. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trial group. J Clin Oncol 1997;15:1638-45.
33. Canellos GP. Long-term follow up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-8.
34. Duggan DB, Petroni GR, Johnson JLJ, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14.
35. Martinelli G, Cocorocchio E, Peccatori F, et al. ChlVPP/ABVVP, a first line "hybrid" combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. Br J Haematol 2004;125:584-9.